Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of GT20029 gel in acne vulgaris
CTR20240799Phase 2Active
- Sponsor
- Kintor Pharmaceutical Limited
- Start
- Jun 2024
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GT20029, sponsored by Kintor Pharmaceutical Limited. Started Jun 2024; status: active.
02
Drugs
GT20029
Beyond the preview
Go deeper on CTR20240799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240799.